Maria Mitsogianni's research while affiliated with Hygeia Hospital and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (11)
Current management of non-metastatic muscle invasive bladder cancer (MIBC) includes radical cystectomy and cisplatin-based neoadjuvant chemotherapy (NAC), offers a 5-year survival rate of approximately 50% and is associated with significant toxicities. A growing body of evidence supports the role of liquid biopsies including circulating tumour DNA...
Introduction:
Prostate cancer is the most common malignancy in the male. Androgen-deprivation therapy (ADT) has been the mainstay in the treatment of metastatic prostate cancer however, due to the outgrowth of castration-resistant cell population the disease inevitably progresses to an aggressive, difficult to handle stage.
Areas covered:
We hav...
Objective: The aim of this study is to determine if patients undergoing radical retropubic prostatectomy with localized prostate cancer under combined (epidural-spinal) anaesthesia have any benefit over patients undergoing the procedure under general anaesthesia.
Material and Methods: Patients with clinically localised prostate cancer, scheduled fo...
Standard systemic therapy of advanced renal cell carcinoma (RCC) involves targeting angiogenesis, mainly through tyrosine kinase inhibitors (TKI) against the vascular endothelial growth factor receptor (VEGFR) pathway and targeting the immune checkpoints, namely, programmed death-1 (PD-1) or its ligand (PD-L1), and cytotoxic T-lymphocyte-associated...
Liposarcomas of the spermatic cord are extremely rare, with less than 200 cases in the literature. We present a case of sclerosing mixed with myxoid liposarcoma of the left spermatic cord in a 55-year-old male patient, mimicking an inguinal hernia on pre-operative ultrasound. The patient underwent orchidectomy and is currently on follow-up surveill...
BRAF/MEK inhibitors are considered standard of care in the treatment of advanced BRAF-mutated malignant melanoma, and have been, in rare cases, associated with granulomatous reactions, mostly limited to skin lesions. The present study reported the case of a patient with metastatic melanoma developing a sarcoid-like reaction manifesting as asymptoma...
Purpose
Health-related quality of life (HRQoL) assessment has become an integral part of clinical research across different disciplines. However, the degree of incorporation of QoL standardized questionnaires in daily routine is variable. This survey study examined how HRQoL is perceived and utilized among urologists from the Hellenic Urological As...
Lymphoepithelioma-like carcinoma of the urinary bladder is a rare variant of infiltrating urothelial carcinoma. Diagnostic and therapeutic manipulations are not yet standardised, due to the rarity of the tumour, with surgery and chemotherapy being reported as potential therapeutic options. We report on a case of lymphoepithelioma-like carcinoma of...
Introduction:
Pulmonary blastoma is a rare malignancy, accounting for less than 0.5% of primary lung tumors. It belongs to the group of pulmonary sarcomatoid carcinomas, and it is typically characterized by a biphasic pattern of an epithelial and a mesenchymal component. Only a few hundred cases have been reported worldwide. The aim of this study...
Citations
... The treatment for hormone-sensitive metastatic prostate cancer commonly entails the use of androgen deprivation therapy (ADT), which, by suppressing or blocking testosterone, deprives the tumor of a key factor driving its growth [1][2][3]. Since approximately 11.6% of males will be affected by prostate cancer in their lifetime, the number of men undergoing this treatment is large and growing [4,5]. ...
... This improvement can be attributed to significant advancements in treatment [3][4][5]. The treatment landscape is rapidly evolving, and there are currently several therapeutic options available for second-line therapy, including dual immune checkpoint inhibition (ICI) or a combination of immunotherapy ICIs and antiangiogenic tyrosine kinase inhibitors (TKI) [9]. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/655146941947906-1533210611322_Q64/Maria-Papathanassiou-2.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/775904041132032-1562001347250_Q64/Panagiotis-Vlachostergios.jpg)
... However, both sarcoidosis and sarcoid-like reactions (that do not fulfill all the diagnostic criteria) are reported in adults treated for cancer, most frequently in patients with melanoma treated using BRAF/MEKi. The reported incidence was 5.7%, and 11% for vemurafenib monotherapy and dabrafenib/trametinib combination, respectively [8][9][10] . Onset following BRAF/MEKi initiation was at 9-months (median) (range: 1-21). ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/272441020776471-1441966409685_Q64/Gerasimos-Aravantinos.jpg)
... Urethral location is extremely rare with only one case described prior to this case report (8). In the urinary bladder and upper urothelial tract, LELC usually presents with gross hematuria (9)(10)(11). ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/673250329763843-1537526795241_Q64/Lazaros-Tzelves.jpg)
... The typical imaging findings are round or oval solid masses with smooth edges and lobed surroundings, but generally without "burr" formation. 3 When the tumor invades the bronchus, pleura, or pericardium, it may show corresponding imaging features, including obstructive pneumonia, pleural fluid, and atelectasis. 4 Therefore, PB is easily misdiagnosed or ignored clinically. ...
... Unfortunately, the development of resistance to hormone therapy, even years after stopping the treatment [5], poses a clinical challenge by narrowing down the available treatment options and worsening disease prognosis [6,7]. Notably, HER2 overexpression (HER2+) in breast cancer is correlated with faster tumour growth and higher risk of recurrence, however, it also provides a specific target for antibody-based cancer therapy with, e.g., trastuzumab (Herceptin) [8][9][10]. A breast cancer subtype that no longer express functional hormone receptors (ER-/PR-) or HER2 is called triple-negative breast cancer (TNBC). ...
... The interest in development of inhibitors targeting PD-1 has been generated primarily on the basis of phase I/II clinical studies. Such studies of checkpoint inhibitors like pembrolizumab and nivolumab have demonstrated highly promising and durable immune responses in patients with solids tumors like melanoma, renal cell carcinoma and non-small-cell lung carcinoma [92][93][94][95][96][97]. ...
